Reverse-turn mimetics and method relating thereto
Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins as well as their prodrugs are disclosed. Such reverse-turn mimetic structures and prodrugs have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds and prodrugs for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.
1. A compound having the following formula (I):
wherein
R a is indolyl substituted with one or more substituents selected from the group consisting of alkyl, acyl, oxo, aryl, arylalkyl, acyloxyalkyl, amidino, alkoxy, cyano, guanidino, alkylguanidino, dialkylguanidino, halo, hydrazinyl, hydroxyl, pyridinyl, nitro, —OC(O)—R d , —N(R d ) 2 , —C(O)OR d , —C(O)N(R d ) 2 , —N(R d )C(O)OR d , —N(R d )C(O)R d , —N(R d )S(O) t R d (where t is 1 or 2), —S(O) t OR d (where t is 1 or 2), —S(O) p R d (where p is 0, 1 or 2), and —S(O) t N(R d ) 2 (where t is 1 or 2) where each R d is independently hydrogen, alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl;
R b is hydrogen;
R c is hydroxyl, amidosulfonate, phosphate, monosodiumphosphate, or disodiumphosphate,
as an isolated stereoisomer or a mixture of stereoisomers or as a pharmaceutically acceptable salt.
2. The compound of claim 1 wherein R a is substituted indolyl substituted with one or more substituents selected from the group consisting of alkyl, acyl, aryl, arylalkyl, alkoxy, cyano, halo, pyridinyl, —S(O) 2 R d where R d is alkyl or aryl.
3. A compound selected from the group consisting of:
4. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
5. A compound having the following formula (II):
wherein
R a is indolyl substituted with one or more substituents selected from the group consisting of alkyl, acyl, oxo, aryl, arylalkyl, acyloxyalkyl, amidino, alkoxy, cyano, guanidino, alkylguanidino, dialkylguanidino, halo, hydrazinyl, hydroxyl, pyridinyl, nitro, —OC(O)—R d , —N(R d ) 2 , —C(O)OR d , —C(O)N(R d ) 2 , —N(R d )C(O)OR d , —N(R d )C(O)R d , —N(R d )S(O) t R d (where t is 1 or 2), —S(O) t OR d (where t is 1 or 2), —S(O) p R d (where p is 0, 1 or 2), and —S(O) t N(R d ) 2 (where t is 1 or 2) where each R d is independently hydrogen, alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl;
R c is hydroxyl, amidosulfonate, carbonylsulfamate, phosphate, monosodiumphosphate, or disodiumphosphate,
as an isolated stereoisomer or a mixture of stereoisomers or as a pharmaceutically acceptable salt.
6. The compound of claim 5 wherein R a is substituted indolyl substituted with one or more substituents selected from the group consisting of alkyl, acyl, aryl, arylalkyl, alkoxy, cyano, halo, pyridinyl, —S(O) 2 R d where R d is alkyl or aryl.
7. A compound selected from the group consisting of:
8. A pharmaceutical composition comprising a compound according to claim 5 and a pharmaceutically acceptable carrier.